The anti-ED drug market has huge development potential and is attracting domestic pharmaceutical companies to "grab food"

ED is a common male sexual dysfunction.
The prevalence rate of males over 40 is as high as 55%.
About half of the patients are moderately affected groups.
Drugs can be used to improve symptoms.
Therefore, it is an anti-ED.
The development of the pharmaceutical industry has laid a solid foundation for development
.
At present, the drugs for the treatment of ED in the domestic market mainly include sildenafil, vardenafil, and tadalafil.
Among them, tadalafil is a long-acting drug, and the remaining two types of drugs are short-acting drugs.
Use it just before you need it
.
According to the data, in 2020, the total sales of the above three types of anti-ED drugs will exceed 3.
5 billion yuan in the terminals of Chinese public medical institutions and physical pharmacies in Chinese cities, a year-on-year increase of 6.
7%
.
Among them, sildenafil is a large-scale product in the ED market, and retail pharmacies are its main sales channels.
In 2019, the terminal sales of retail pharmacies in Chinese cities exceeded 2.
3 billion yuan
.
Data shows that in recent years, the domestic market of sildenafil has continued to expand.
In 2020, the terminal sales of physical pharmacies in Chinese cities exceeded 2.
5 billion yuan, a year-on-year increase of 8.
57%
.
It is worth mentioning that with the efforts of local enterprises, the market share of the original research manufacturer Pfizer has continued to decline, from 52.
60% in 2017 to 44.
08% in 2020
.
For the continuous expansion of the domestic anti-ED market, the industry believes that this is mainly due to the rapid increase in the volume of generic drugs that continues to promote the rapid growth of the market scale of China's anti-ED drug industry
.
It is understood that from 2014 to April 2020, there were 13 approved sildenafil products and 9 approved tadalafil products by local enterprises in China
.
It is worth noting that in recent years, as the ED diagnosis rate is gradually increasing, the growth space of China's ED market is still increasing
.
The industry estimates that about 10% of men worldwide suffer from ED
.
According to this calculation, anti-ED drugs will have huge market potential in China
.
Such an attractive cake will of course attract many pharmaceutical companies to take a share of it
.
It is understood that the domestic anti-ED market has ushered in many new eaters recently.

.
For example, 4 types of generic drugs, Sildenafil Citrate Tablets by HEC Pharmaceuticals, and 1.
1 New Drugs of Yuekang Pharmaceuticals, AIRIS® Sildenafil Citrate Tablets, have all been approved for marketing one after another
.
According to public information, Sildenafil Citrate is a selective inhibitor of phosphodiesterase type 5 (PDE-5) developed by Pfizer for the treatment of erectile dysfunction (ED)
.
According to incomplete statistics, in addition to the above companies, in 2021 alone, there will be Haisco, Huilun Jiangsu Pharmaceutical, Jiangsu Yabang Epson Pharmaceutical, Fujian Guangshengtang Pharmaceutical, Shenzhen Haiwang Pharmaceutical, Yangzijiang Pharmaceutical, China Resources SECCO, Yuekang Pharmaceuticals, Sunshine Pharmaceuticals, Hunan Qianjin Xiangjiang Pharmaceuticals, Guangzhou Langsheng Pharmaceuticals, Luoxin Pharmaceuticals, and Grand Pharmaceuticals 13 PDE-5 selective inhibitors have been approved for marketing for the treatment of ED
.
However, it should be noted that although China's anti-ED drug industry has been in a stage of rapid development in recent years, there is still a long way to go with the penetration rate of developed countries.
Therefore, China's anti-ED drug industry still has a lot of room for improvement.
The market size in 2024 is expected to approach 10 billion yuan
.